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Abstract
Background: Pregnancy triggers well-known alterations in maternal glucose and lipid balance but its overall effects
on systemic metabolism remain incompletely understood.
Methods: Detailed molecular profiles (87 metabolic measures and 37 cytokines) were measured for up to 4260
women (24–49 years, 322 pregnant) from three population-based cohorts in Finland. Circulating molecular
concentrations in pregnant women were compared to those in non-pregnant women. Metabolic profiles were also
reassessed for 583 women 6 years later to uncover the longitudinal metabolic changes in response to change in
the pregnancy status.
Results: Compared to non-pregnant women, all lipoprotein subclasses and lipids were markedly increased in
pregnant women. The most pronounced differences were observed for the intermediate-density, low-density and
high-density lipoprotein triglyceride concentrations. Large differences were also seen for many fatty acids and
amino acids. Pregnant women also had higher concentrations of low-grade inflammatory marker glycoprotein
acetyls, higher concentrations of interleukin-18 and lower concentrations of interleukin-12p70. The changes in
metabolic concentrations for women who were not pregnant at baseline but pregnant 6 years later (or vice versa)
matched (or were mirror-images of) the cross-sectional association pattern. Cross-sectional results were
consistent across the three cohorts and similar longitudinal changes were seen for 653 women in 4-year and
497 women in 10-year follow-up. For multiple metabolic measures, the changes increased in magnitude across
the three trimesters.
Conclusions: Pregnancy initiates substantial metabolic and inflammatory changes in the mothers.
Comprehensive characterisation of normal pregnancy is important for gaining understanding of the key
nutrients for fetal growth and development. These findings also provide a valuable molecular reference in
relation to studies of adverse pregnancy outcomes.
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Background
Pregnancy induces remarkable changes in maternal me-
tabolism to support fetal demands [1, 2]. Maternal circu-
lating glucose is an essential nutrient for the developing
fetus [3] and during pregnancy women become increas-
ingly insulin resistant, particularly from the second tri-
mester onwards [4]. In the third trimester, maternal
fasting insulin levels increase by over 30%, while fasting
glucose concentrations decrease by about 10%, despite
increased insulin resistance [1, 5]. In addition to glucose,
there is evidence that circulating lipids and amino acids
are also important nutrients for the fetus [1, 2]. During
the third trimester, maternal circulating lipid concentra-
tions dramatically increase, with triglycerides being
elevated by approximately twofold, and total and low-
density lipoprotein (LDL) cholesterol by some 30–50%
[1, 5–7]. Maternal circulating amino acid concentrations
are also suggested to be altered largely in response to in-
creased protein synthesis for placental and fetal growth
[8]. In addition, pregnancy triggers considerable changes
in the maternal immune system, with circulating cyto-
kines being reprogrammed to sustain the integrity of the
allograft fetus [9].
Most of the changes in maternal metabolism and
inflammatory status are considered to be normal
physiological responses to support fetal growth and
development. These changes typically return to pre-
pregnancy states soon after delivery [2]. However, in
some women the changes may be harmful and re-
lated to adverse pregnancy outcomes, for example,
gestational diabetes, hypertensive disorders, and pre-
term birth [2, 10, 11]. These adverse pregnancy out-
comes are associated with increased future risk of
diabetes and cardiovascular disease both in mothers
and offspring, though the extent to which these are
causal or reflect pre-existing maternal risk is unclear
[2]. Characterising the normal metabolic and inflam-
matory changes in pregnancy is crucial for gaining
understanding of the key nutrients for normal fetal
growth and development, and for identifying meta-
bolic and inflammatory changes in pregnancy that
might herald the risk of adverse outcomes. However,
so far, most epidemiological studies on the metabolic
effects of pregnancy have had very small numbers of
individuals (typically only a few dozen pregnant
women) and lack replication. The metabolic informa-
tion is generally limited to standard lipids and glu-
cose [1, 5], and studies on the effects of pregnancy
on mothers’ systemic metabolism are lacking. The
aim of this study is to comprehensively characterise
the maternal systemic metabolism across a wide
range of metabolic and inflammatory measures in
both cross-sectional and longitudinal settings coupled
with replication.
Methods
Study population
Serum metabolic profiles were quantified in three inde-
pendent population-based cohorts from Finland. Sam-
ples for profiling were collected in 1997 for participants
in the Northern Finland Birth Cohort 1966 (NFBC1966,
n = 2963 women aged 31) [12, 13], in 2001 for those in
the Cardiovascular Risk in Young Finns Study (YFS, n =
1239 women aged 24–39) [14], and in 1997 for those in
the FINRISK1997 study (FINRISK1997, n = 2101 women
aged 24–49) [15]. Overnight fasting samples were ob-
tained for NFBC1966 and YFS, whereas semi-fasting
samples (median fasting time 5 hours) were obtained
for FINRISK1997. Further details of the study popula-
tions are provided in Additional file 1: Supplementary
Methods. We excluded women whose information on
pregnancy status at the time of metabolic profiling
was missing (n = 136); women using oral contraception
(n = 1279); and women with a fasting glucose ≥7 mmol/L
(n = 33, of which two were pregnant), systolic blood pres-
sure ≥140 mmHg, or diastolic blood pressure ≥90 mmHg
(n = 595; 13 pregnant). After these exclusions, 4260
women, of whom 322 were pregnant (Table 1), were in-
cluded in the study. A subset of 583 women from YFS
attended a 6-year follow-up (baseline in 2001; follow-up
in 2007) at which their clinical and pregnancy status were
assessed and the metabolic profiling performed again. In
these women prospective changes in their metabolic pro-
files, with respect to the change in their pregnancy status,
were examined. Cytokine profiles were analysed for 2321
women from FINRISK1997 (1415 women, 69 pregnant)
and YFS in 2007 (906 women, 35 pregnant).
We were not able to exclude breastfeeding women or
those women who were pregnant with multiple babies
because such information was not available in all the co-
horts. However, in NFBC1966 where the information on
the number of babies per pregnancy was available, there
were only two pregnant women with a twin pregnancy
and none with higher multiples. We therefore assume
that the vast majority of the data in these population-
based cohorts are on singleton pregnancies. Information
on breastfeeding was available in YFS; 6.5% of non-
pregnant women were breastfeeding. The metabolic as-
sociations with pregnancy were almost identical whether
the data for breastfeeding women were excluded from
those for non-pregnant women or not (Additional file 1:
Figure S1).
Information on pregnancy and covariates
Pregnancy status, parity, current smoking, and alcohol
consumption were assessed by questionnaires. In YFS,
the participants reported the gestational age (in weeks)
at the time of blood sampling. In NFBC1966, the gesta-
tional age (in weeks) at the time of blood sampling was
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calculated based on a birth registry. Information on the
gestational age was not available for the participants in
FINRISK1997. Weight, height and blood pressure were
assessed in clinics using established protocols.
In the primary analyses, we compared pregnant (n =
322) to non-pregnant women (n = 3938). In the second-
ary analyses, we compared pregnant women in different
trimesters to non-pregnant women using data from
NFBC1966 and YFS. Profiles for women in their first tri-
mester (pregnancy length ≤12 weeks, n = 48), second tri-
mester (pregnancy length >12 weeks and ≤28 weeks, n =
116), and third trimester (pregnancy length >28 weeks,
n = 67) were compared to those of the non-pregnant
women (n = 2588). Information on gestational age was
missing for 20 pregnant women who were therefore ex-
cluded from these analyses.
Molecular profiling
We analysed 124 biomarkers, including 87 metabolic
measures and 37 cytokines. Eighty out of the 87 meta-
bolic measures were quantified by a high-throughput
serum nuclear magnetic resonance (NMR) metabolo-
mics platform [16, 17]. These measures represent a
broad molecular signature of systemic metabolism and
cover multiple metabolic pathways, including lipoprotein
lipids and subclasses, fatty acids, amino acids, and
glycolysis-related metabolites. The NMR-based meta-
bolic profiling has previously been used in multiple
large-scale epidemiological and genetic studies [18–25]
and the experimentation is described elsewhere [16, 17,
26]. The seven other metabolic measures assessed were
high-sensitivity C-reactive protein (CRP); vitamin D; sex
hormone-binding globulin (SHBG); and the hormones in-
sulin, leptin, adiponectin and testosterone. Additionally,
37 cytokines were analysed using Bio-Rad’s Bio-Plex As-
says. Details of these measurements are given in
Additional file 1: Supplementary Methods.
Statistical analyses
The metabolic and cytokine measures were log-
transformed because their distributions were generally
skewed (Additional file 1: Figure S2) and likely to result
in non-normal residuals in the regression analyses. The
measures were then scaled to standard deviations (SD)
in each cohort. Due to the correlated nature of the data,
we used principal component analysis to evaluate the
appropriate number of independent tests for multiple
testing correction [22, 24]. Sixty-one principal compo-
nents explained over 99% of the variation in the mo-
lecular measures across all three cohorts (Additional
file 1, Table S1). Therefore, P < 0.0008 (0.05/61) was
used to infer statistical significance [22, 24].
For the cross-sectional analyses, a linear regression
model was fitted for each outcome measure (concentra-
tion of a metabolic or a cytokine measure) using preg-
nancy status as the explanatory variable. Non-pregnant
women were used as the reference group, so the associ-
ation magnitudes denote the difference in each outcome
measure between pregnant and non-pregnant women.
Association magnitudes are reported in SD units to
ease the comparison across multiple measures. Differ-
ences in the original units of the metabolic and cyto-
kine measures and the percentage differences are given
in Additional file 1: Supplementary Material. All three
cohorts were analysed separately and the results com-
bined using fixed-effect inverse variance-weighted
meta-analysis after confirming the consistency across
the cohorts. In the main analyses we adjusted for age.
Table 1 Characteristics of the study participants
Characteristics NFBC1966 YFS FINRISK1997
Non-pregnant Pregnant Non-pregnant Pregnant Non-pregnant Pregnant
Number 1782 191 806 60 1350 71
Gestational age at blood sampling (week) – 22 (13–29) – 23 (15–30) – –
Age (year) 31 (0) 31 (0) 32 (5) 31 (5) 37 (7) 32 (5)
Weight (kg) 65 (13) 67 (11) 67 (13) 71 (12) 66 (12) 70 (13)
Waist (cm) 79 (11) 82 (12) 80 (11) 85 (10) 77 (10) 83 (13)
Hip (cm) 97 (8) 97 (8) 100 (9) 102 (7) 99 (8) 101 (9)
BMI (kg/m2) 24 (4) 24 (4) 24 (5) 26 (4) 25 (4) 26 (4)
Systolic blood pressure (mmHg) 117 (10) 116 (9) 111 (10) 109 (11) 119 (10) 114 (11)
Diastolic blood pressure (mmHg) 73 (8) 66 (10) 68 (8) 61 (9) 74 (8) 68 (9)
Smoking prevalence (%) 38 25 20 10 23 8
Alcohol usage (g/day) 2.1 (0.6–5.7) 1.0 (0.0–3.5) 3.3 (0.0–8.2) 0.0 (0.0–0.0) 1.8 (0.0–7.0) 0.0 (0.0–0.0)
Parity (n) 2 (1–2) 1 (0–2) 1 (0–2) 1 (0–2) – –
Values are mean (SD) for normally distributed and median (interquartile range) for skewed variables. Information on whether women have given birth before was
not available for FINRISK1997. BMI: body mass index
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In the second set of models we additionally adjusted for
body mass index (BMI), parity, mean arterial pressure
(MAP), current smoking and alcohol consumption.
Similar linear models were used to determine the meta-
bolic differences between trimesters and non-pregnant
women using data from NFBC1966 and YFS.
Those 583 women from the YFS cohort who had both
baseline and 6-year follow-up data were classified as
pregnant at follow-up (non-pregnant at baseline but
pregnant at follow-up, n = 18), pregnant at baseline
(pregnant at baseline but non-pregnant at follow-up,
n = 44) and those non-pregnant at both time points
(n = 519). Two women who were pregnant at both
baseline and follow-up were excluded from the ana-
lysis. The 6-year changes in metabolic concentrations
were compared between (1) women who were preg-
nant at follow-up, and (2) women who were pregnant
at baseline, and women who were non-pregnant at
both time points. The longitudinal models were ad-
justed for baseline age and further for the baseline
parity and 6-year change in BMI, MAP, smoking and
alcohol use. The longitudinal analyses were addition-
ally replicated for 653 women who had 4-year follow-
up data (from year 2007 to 2011 in YFS) and 497
women who had 10-year follow-up data (from year
2001 to 2011 in YFS). Details of these data are de-
scribed in Additional file 1: Supplementary Methods.
Results
The characteristics of the study participants are given in
Table 1. The pregnant women, in comparison to those
non-pregnant, tended to have lower diastolic blood pres-
sure, smoke less and consume less alcohol.
Lipoprotein-related measures in pregnancy
Figure 1 (left panel) illustrates the cross-sectional associ-
ations between pregnancy and 44 lipoprotein-related
measures. The metabolic differences between pregnant
and non-pregnant women are given in SD units in
Additional file 1: Table S2, in absolute physiological
units in Additional file 1: Table S3 and as a percentage
difference relative to non-pregnant women in Additional
file 1: Table S4. Pregnancy was associated with increased
levels of almost all lipoprotein-related measures (P < 0.0008
for 41 out of 44 measures meta-analysed). The associ-
ation magnitudes were substantial, with a median of
0.9 SD unit increments (interquartile range 0.8–1.1
SDs), corresponding to a median of a 33% (interquar-
tile range 25–51%) higher concentration in pregnant
than in non-pregnant women. The increase in total
lipids was similar across the smaller very-low-density
(VLDL), intermediate-density (IDL) and low-density
(LDL), and the larger high-density (HDL) lipoprotein
subclasses. Pregnancy was positively associated with all
cholesterol, triglyceride and phospholipid concentra-
tions as well as with both apolipoprotein B and A-I.
The differences for IDL, LDL and HDL triglycerides were
approximately twofold in comparison to VLDL triglycer-
ides. In contrast, differences in cholesterol and phospho-
lipid concentrations in all these main lipoprotein fractions
were broadly similar. The percentage of esterified choles-
terol (of total cholesterol) did not differ between pregnant
and non-pregnant women. Pregnancy was positively asso-
ciated with the average size of VLDL and HDL particles
but not with the average size of LDL particles.
Fatty acids in pregnancy
Figure 2 (left panel) displays the cross-sectional associa-
tions between pregnancy and multiple fatty acid mea-
sures. The circulating concentrations of all fatty acids
were considerably increased during pregnancy, ranging
approximately between 1.0 and 1.5 SDs, being equivalent
to 24–56% higher concentrations relative to non-
pregnant women. However, the proportions of individual
fatty acids (relative to total fatty acids) exhibited a di-
verse association pattern. The proportions of saturated
and monounsaturated fatty acids as well as the propor-
tion of docosahexaenoic acid (DHA) were increased. In
contrast, the proportion of omega-6 fatty acids, includ-
ing linoleic acid, were decreased.
Metabolites, inflammatory markers and hormones in
pregnancy
Figure 3 (left panel) shows the concentration differences
in multiple circulating biomarkers between pregnant and
non-pregnant women. The amino acids displayed a het-
erogeneous association pattern: strong positive associa-
tions for alanine, phenylalanine and histidine; negative
associations for glutamine, glycine, valine and tyrosine;
and null associations for isoleucine and leucine. Glucose,
glycerol and acetoacetate concentrations were modestly
decreased but lactate and pyruvate increased in the
pregnant women. Creatinine and albumin concentra-
tions were decreased and those of the low-grade in-
flammatory markers, glycoprotein acetyls (GlycA) [27]
and CRP, increased. Of the hormones, testosterone and
leptin concentrations were increased, as was that of
SHBG, which displayed the strongest association across
the molecular profile (2.5 SDs; equivalent to 483%
higher concentration in pregnant women than in the
non-pregnant women).
The associations with lipoprotein-related measures,
fatty acids, low-molecular-weight metabolites, inflamma-
tory markers and hormones were highly consistent
across the three cohorts (Additional file 1: Figure S3).
The results remained very similar with further adjust-
ments for parity, BMI, MAP, smoking and alcohol
(Additional file 1: Figure S4). To assess how much the
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metabolic signature of pregnancy could reflect high
concentrations of circulating lipids, it was compared to
the metabolic association patterns of higher non-
VLDL-triglycerides (the sum of IDL, LDL and HDL tri-
glycerides) and higher total fatty acids in non-pregnant
women (Additional file 1, Figure S5). These analyses
support an interpretation that many of the metabolic
changes seen are likely specific for the pregnancy
status.
Correlation network analysis
Multivariate correlation network analyses were con-
ducted to assess potential differences in metabolic asso-
ciations between pregnant and non-pregnant women;
Fig. 1 Cross-sectional and longitudinal associations between pregnancy and lipoprotein-related measures. Left panel, cross-sectional analyses in
which pregnant women (n = 322) were compared to non-pregnant women (n = 3938). The associations were adjusted for age and meta-analysed
for three Finnish population-based cohorts. Middle panel, longitudinal analyses in which women who were pregnant at follow-up (but not at
baseline) (n = 18) were compared to women who were non-pregnant at both time points (n = 519). Right panel, longitudinal analyses in which
women who were pregnant at baseline (but not at follow-up) (n = 44) were compared to women who were non-pregnant at both time points
(n = 519). Longitudinal associations were adjusted for baseline age. Open diamonds indicate P ≥ 0.0008, closed diamonds indicate P < 0.0008. C
cholesterol, CI confidence interval, HDL high-density lipoprotein, IDL intermediate-density lipoprotein, LDL low-density lipoprotein, PL phospholipids,
SD standard deviation, TG triglycerides, VLDL very-low-density lipoprotein
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Fig. 2 Cross-sectional and longitudinal associations between pregnancy and fatty acids. The study design is as explained in the legend for Fig. 1.
The percentage sign (%) refers to the proportion of an individual measure of the total fatty acids. Open diamonds indicate P ≥ 0.0008, closed
diamonds indicate P < 0.0008. CI confidence interval, FA fatty acids, MUFA monounsaturated fatty acids, PUFA polyunsaturated fatty acids, SD
standard deviation
Fig. 3 Cross-sectional and longitudinal associations between pregnancy and metabolic, inflammatory and hormonal measures. The study design
is as explained in the legend for Fig. 1. Open diamonds indicate P ≥ 0.0008, closed diamonds indicate P < 0.0008. CI confidence interval, SD
standard deviation, SHBG sex hormone-binding globulin
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these analyses and the results are described in detail in
Additional file 2. Briefly, a higher degree of pair-wise
correlations was observed in pregnant (mean Spearman
|r| = 0.39) compared to non-pregnant women (mean |r| =
0.29). A pronounced node difference was noted for SHBG,
together with triglycerides in multiple lipoprotein categor-
ies (‘Triglyceride enrichment’ community), alanine and
phenylalanine (‘Amino acid’) and various fatty acids (‘Fatty
acid composition’). These nodes shared a similar pattern
of higher inter-community connectivity for the preg-
nant than for the non-pregnant women. In general, the
correlation network analyses suggest that pregnancy is
acting as a metabolic stressor that amplifies intrinsic
patterns of metabolism.
Metabolic changes in response to change in pregnancy
status
Figures 1, 2 and 3 (middle and right panels) illustrate
six-year changes in 84 metabolic measures in response
to change in pregnancy status (follow-up data were
missing for leptin, SHBG and testosterone). In the mid-
dle panels, the metabolic changes in women who were
pregnant at follow-up but not at baseline were compared
to those of women who were non-pregnant at both time
points. In the right panels, the metabolic changes in
women who were pregnant at baseline but not at follow-
up were compared to those of women who were non-
pregnant at both time points. Substantial metabolic
changes were observed for women who were pregnant
at follow-up (middle panel); the association magnitudes
were highly similar to those observed in the cross-
sectional setting (left panel). Pronounced metabolic
changes were also observed for women who were preg-
nant at baseline (right panel); the absolute association
magnitudes again matched the cross-sectional setting,
but they were in the opposite direction. The overall
consistency between the longitudinal metabolic changes
in women pregnant at follow-up and the cross-sectional
metabolic differences followed a straight line with a
slope of 1.04 ± 0.04 (R2 = 0.90; Fig. 4, left panel). Simi-
larly, the magnitudes of the metabolic associations for
women pregnant at baseline and those of cross-sectional
associations also fell in a straight line with R2 = 0.93 but
with a negative slope of −1.02 ± 0.03 (Fig. 4, right panel).
Differences in the point estimates were noted for DHA
(%) in the longitudinal analysis of women who were
Fig. 4 Correlations between cross-sectional and longitudinal metabolic associations of pregnancy. Left panel, linear fit to summarise the
correspondence between cross-sectional (pregnant women compared to non-pregnant women) and longitudinal associations for women
pregnant at follow-up but not at baseline (in comparison to women non-pregnant at both time points). Right panel, linear fit to summarise
the correspondence between cross-sectional and longitudinal associations for women pregnant at baseline but not at follow-up (in comparison to
women non-pregnant at both time points). Each point represents a single metabolic measure. Horizontal and vertical grey lines denote 95% CIs for the
cross-sectional and longitudinal associations, respectively. The grey shaded areas serve to guide the eye for the slope. A linear fit for the overall
correspondence summarises the match between cross-sectional and longitudinal associations, with R2 denoting the goodness of fit. A slope
of ±1 and R2 = 1 would strongly support the causal effects of pregnancy on the metabolic measures. C cholesterol, CI confidence interval, DHA
docosahexaenoic acid, FA fatty acids, HDL high-density lipoprotein, IDL intermediate-density lipoprotein, LDL low-density lipoprotein, PL phospholipids,
PUFA polyunsaturated fatty acids, SD standard deviation, TG triglycerides, VLDL very-low-density lipoprotein
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pregnant at follow-up but not at baseline, in comparison
with the other longitudinal analysis and cross-sectional
analysis. However, the confidence intervals of these ana-
lyses overlapped, suggesting consistency of the results.
Larger longitudinal studies would be required to ascertain
the relevance of these findings on DHA% in pregnancy.
The longitudinal associations remained similar when fur-
ther adjusted for baseline parity and 6-year change in
BMI, MAP, smoking and alcohol consumption (Additional
file 1: Figures S6 and S7). To assess the consistency of
these longitudinal associations in the YFS cohort, we fur-
ther compared the results from the 6-year follow-up to
those from 4-year (from year 2007 to 2011) and 10-year
follow-up (from year 2001 to 2011). The longitudinal asso-
ciations were highly consistent across the 4-year, 6-year
and 10-year follow-up (Additional file 1: Figure S3).
Metabolic profile during trimesters
Figure 5 shows cross-sectional concentration differences
in 87 metabolic measures between pregnant women in
Fig. 5 Cross-sectional associations between pregnancy trimesters and metabolic measures. Pregnant women in their first (n = 48), second (n = 116)
and third trimester (n = 67) were compared to non-pregnant women (n = 2588). Associations were adjusted for age and meta-analysed for NFBC1966
and YFS. Open circles indicate P ≥ 0.0008, closed circles indicate P < 0.0008. C cholesterol, CI confidence interval, FA fatty acids, HDL high-density
lipoprotein, IDL intermediate-density lipoprotein, LDL low-density lipoprotein, PL phospholipids, MUFA monounsaturated fatty acids, PUFA
polyunsaturated fatty acids, SD standard deviation, SHBG sex hormone-binding globulin, TG triglycerides, VLDL very-low-density lipoprotein
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different trimesters and non-pregnant women (Additional
file 1: Table S5). The differences in SD units, in absolute
physiological units and as percentages relative to non-
pregnant women are given in Additional file 1: Tables S2,
S3 and S4, respectively. During the first trimester many
circulating metabolic concentrations were similar to those
in non-pregnant women, although some clear differences
were already observable: for example, glutamine, creatin-
ine, SHBG and testosterone displayed over 1 SD metabolic
differences. Women in their second or third trimesters of
pregnancy had large metabolic aberrations in comparison
to non-pregnant women, with similar association patterns
as those described earlier (Figs. 1, 2 and 3) when all tri-
mesters were combined. There was a clear trend of in-
creasing metabolic differences in most lipoprotein-related
measures across the trimesters, with median percentage
difference −9% (interquartile range −13% to 0%) for the
first trimester, 34% (interquartile range 28–51%) for the
second trimester, and 59% (interquartile range 39–100%)
for the third trimester. However, HDL-related measures
were similar during the second and third trimesters. The
association pattern across the three trimesters for most of
the absolute concentrations of fatty acids followed that of
the apolipoprotein B-containing lipoprotein subclasses.
However, exceptions were observed for omega-3 fatty
acids and DHA, for which the association pattern across
the three trimesters resembled that of the large HDL sub-
classes and apolipoprotein A-I. The differences in the ma-
jority of the proportions of the fatty acids also had the
tendency to be largest during the third trimester. The
circulating concentrations of multiple low-molecular-
weight metabolites, albumin, inflammatory markers and
hormone-related measures were broadly similar during
the second and third trimesters. The metabolic associa-
tions during the trimesters were highly consistent in
NFBC1966 and YFS (Additional file 1: Figure S8).
Metabolic retention of pregnancy
The metabolic retention of pregnancy was evaluated at
various times postpartum (calculated as the duration
from the delivery to the blood sampling). These analyses
were done in NFBC1966 (serum samples collected at
1997) utilising the birth registry data from 1995 to 1997.
Women postpartum up to 2 months (n = 28), over 2 and
up to 4 months (n = 46), over 4 and up to 6 months
(n = 42) and over 6 and up to 12 months (n = 123) were
compared to those 1–3 years postpartum (n = 389).
There were clear trends of metabolic normalisation
after the delivery. Within 3–6 months postpartum,
most of the metabolic disturbances were back to levels
similar to those in women 1–3 years postpartum
(Additional file 1: Figure S9). We only had the birth
registry data for NFBC1966 so we could not specify the
delivery dates for all the non-pregnant women in this
study. However, according to the NFBC1966 data, only
6.5% of women had given birth within 6 months prior
to blood sampling. When these women were excluded
from the non-pregnant women in the analyses, the
metabolic associations with pregnancy were almost
identical (Additional file 1: Figure S10).
Cytokine profile in pregnancy
The cross-sectional associations of pregnancy with 37
cytokines are illustrated in Additional file 1: Figure S9.
Among interleukins, positive associations were found
with IL-1ra and IL-18 and negative associations with
IL-12p70. In addition, pregnant women had lower levels
of TRAIL, MCP-1, eotaxin and VEGF and higher levels of
HGF and βNGF than non-pregnant women. The abbrevi-
ations of the cytokines are explained in the caption for
Additional file 1: Figure S11.
Discussion
Here we have comprehensively characterised the effects
of pregnancy on maternal systemic metabolism across a
wide range of metabolic and inflammatory measures in
large numbers of women. These findings are important
for a broader metabolic understanding of the physio-
logical changes caused by pregnancy per se that are
likely to be key to normal fetal growth and development.
They also provide a valuable molecular reference in rela-
tion to studies of adverse pregnancy outcomes [2]. The
cross-sectional associations in three population-based
studies consistently showed that pregnancy was associ-
ated with a wide range of metabolic pathways, including
those for lipoproteins, fatty acids, amino acids, inflam-
matory markers and hormones. The metabolic associa-
tions were pronounced, with magnitudes during the
third trimester being generally 1–3 SDs different from
the non-pregnant women. The exceptionally large meta-
bolic effects, together with the consistent results from
longitudinal analyses, indicate that the metabolic aberra-
tions arise as a direct result of pregnancy [28]. The
metabolic changes increased in magnitudes for many
metabolic measures across the trimesters, and the
changes caused by pregnancy generally normalised
within 3–6 months postpartum.
Metabolic adaptation to pregnancy has been widely
studied with respect to glucose metabolism and standard
lipids [1, 5–7]. Observational studies have reported that
decreased circulating glucose and increased triglycerides,
LDL and HDL cholesterol as well as insulin are associ-
ated with pregnancy [1, 5–7]. Our results here confirm
these metabolic changes in pregnant women and their
change patterns and effect sizes with respect to the tri-
mesters. These findings, together with the results for
leptin [29, 30], SHBG and testosterone [31], serve as
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good positive controls for the novel metabolomics ap-
proach taken in this work.
The most pronounced metabolic changes during preg-
nancy were observed in the circulating concentrations of
IDL, LDL and HDL triglycerides. In these lipoprotein
fractions, the increase in triglycerides was more pro-
nounced than the increase in cholesterol and phos-
pholipids, suggesting triglyceride-enrichment of these
circulating lipoprotein particles in pregnancy [32], par-
ticularly during the second and third trimesters. In
contrast, in the VLDL fraction, all these key lipid constit-
uents increased almost in parallel with each other.
Similar results have been reported previously in small
longitudinal studies [32, 33], with a further suggestion
that the triglyceride-enrichment in various lipoprotein
fractions would be related to oestrogen-induced en-
hanced VLDL production and decreased activity of
lipoprotein lipase and hepatic lipase during pregnancy.
Maternal triglycerides are widely considered to be an
important nutrient for fetal growth. Various observa-
tional studies have shown that higher maternal triglycer-
ide concentrations are associated with larger neonatal fat
mass and higher birth weight [34–37]. However, a recent
Mendelian randomisation analysis challenged the notion
that maternal triglycerides would be causally related to
birth weight [3]. The triglyceride-enrichment in IDL,
LDL and HDL observed here suggests a specific role of
maternal triglycerides in different lipoprotein fractions.
This points to a potential value of further research to as-
sess the causal relations between maternal triglycerides
carried in different lipoprotein particles and birth weight.
Fatty acids are required by the developing fetus to sup-
port rapid cellular growth and activity [38]. Our results
showed that total circulating maternal fatty acid concen-
tration gradually increased during pregnancy, in line
with the overall increase in lipoprotein lipids. The fatty
acid composition, relative to total fatty acids, was also
largely modified during pregnancy. Similar findings for
maternal fatty acids and their proportions in plasma
and plasma phospholipids have been reported previ-
ously [39, 40]. DHA may be of particular importance to
fetal brain and retinal development [38]. Omega-3 fatty
acid supplementation during pregnancy appears to in-
crease maternal and fetal DHA concentration [38], but
meta-analysis of randomised controlled trials suggests
that omega-3 fatty acid supplementation, in addition to
an adequate omnivore intake, can only cause a modest
increase in birth weight and seems to have no effects
on birth length or head circumference [41, 42]. The po-
tential effects of maternal omega-3 supplementation
during pregnancy on cognitive and visual development
in early childhood remain inconclusive [43].
Maternal amino acids are considered to be key deter-
minants for fetal growth [1]. Nevertheless, information
on maternal amino acids during pregnancy is sparse and
comes from studies with only small numbers of partici-
pants [8, 44, 45]. A small cross-sectional study (with
some 10 pregnant women in each trimester) found that
most amino acid concentrations decreased during preg-
nancy [44]. However, our cross-sectional and longitu-
dinal findings here consistently indicate that amino acids
actually display a complex association pattern, with
some being markedly elevated (alanine, phenylalanine
and histidine), some depleted (glutamine, glycine, valine
and tyrosine) and some (isoleucine and leucine) not
responding to pregnancy. The association of pregnancy
with branched-chain and aromatic amino acid concen-
trations did not follow the pattern of consistent eleva-
tions previously seen with obesity and insulin resistance
[18, 19, 46]. Thus, it is unlikely that the weight gain or
the development of insulin resistance during pregnancy
underlie these changes in maternal amino acids. The
complex associations of pregnancy with amino acids are
likely to reflect the intricate molecular-specific interplay
between maternal, placental and fetal metabolism [8].
For example, there is evidence that the concentrations of
some amino acids are generally higher in umbilical cord
plasma than in maternal circulation at delivery [8].
Amino acids cross the placenta via a combination of
multiple active transport systems [47]. Dietary interven-
tions during pregnancy have shown that an increase in
maternal circulating amino acid concentrations does not
appear to affect their circulating concentrations in the
umbilical cord or in the neonate [8]. These findings sug-
gest a robust placental transporting system in adequately
nourished mothers. However, in the present study we
are unable to explore these maternal–fetal interactions.
The maternal immune system is challenged by the
conflicting demands of maintaining robust immune re-
activity to protect both the mother and the fetus while
at the same time tolerating highly immunogenic alloanti-
gens to sustain fetal integrity [48]. We found that con-
centrations of the low-grade inflammatory markers CRP
and GlycA were clearly increased during pregnancy, sug-
gesting the up-regulation of systemic maternal inflam-
mation. The new inflammatory marker, GlycA, which is
quantified via the serum NMR metabolomics platform,
has recently been shown to be associated with both
acute-phase and chronic inflammation, as well as being
related to increased neutrophil activities [27, 49]. Eleva-
tion of GlycA during pregnancy may thereby suggest an
enhancement of maternal innate immunity. With respect
to adaptive immunity, previous studies have suggested
that normal pregnancy polarises the immune response
towards the T helper 2 (Th2) response [9, 48, 50]. This
notion is consistent with our findings of increased circu-
lating IL-18 but decreased levels of IL12p70, which are
important regulators of the Th2/Th1 balance [9, 50].
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Metabolic and immunological changes in the mothers
predominantly occur to the benefit of the fetus. How-
ever, some of these changes may be unfavourable to the
mothers. Hypertriglyceridaemia, elevated LDL and
remnant cholesterol, insulin resistance, and up-regulated
inflammation during pregnancy are all features related
to the increased risk of cardiometabolic diseases. In
addition, our results here indicate that multiple new bio-
markers for cardiovascular diseases [17, 20] show un-
favourable changes during pregnancy; these include
elevated concentrations of phenylalanine and the in-
creased proportion of monounsaturated and decreased
proportions of omega-6 fatty acids. Although we found
that pregnancy-related metabolic alterations generally
normalise soon after delivery (Additional file 1: Figure S9),
there is some evidence that repeated pregnancies might
predispose women to higher cardiovascular risk at older
age [51, 52]. It has been reported that the association be-
tween parity and cardiovascular risk is J-shaped, with two
births representing the lowest risk [51, 52]. Compared to
women with two births, women with five or more births
had a 66% higher risk of cardiovascular disease, the associ-
ation remaining robust when adjusting for socioeconomic
status and pregnancy complications [52]. However, it re-
mains unclear whether the association between parity and
cardiovascular risk indicates a causal relationship [2].
Oral contraceptives are used to prevent pregnancy by
mimicking the reproductive hormone status of natural
pregnancy through the supplementation of a combin-
ation of oestrogen and progestin (combined oral contra-
ceptive pills; COCPs) or progestin-only contraceptives
(POCs). Understandably, this simple mimic cannot repli-
cate the complex physiological effects of natural preg-
nancy and the multilevel interactions between the
mother, the placenta and the fetus. This is in line with
our findings that there is little correspondence in the
pattern of cytokine changes in pregnant women and
those using COCPs [53]. Interestingly, however, the pat-
tern of metabolic changes for lipoprotein measures, fatty
acids, amino acids and low-grade inflammatory markers
during pregnancy has a strong resemblance to the one
caused by COCPs. Though the absolute metabolic
changes are stronger in the case of pregnancy, the direc-
tion of change is generally consistent with that in
women who use COCPs. On the other hand, the meta-
bolic effects of POCs are weak or negligible [53]. These
findings imply that oestrogen plays a key role in the
regulation of maternal metabolism.
Owing to the population-based design of our cohorts,
we were not able to look at how the circulating meta-
bolic measures relate to potential pregnancy complica-
tions or perinatal outcomes. However, it is an important
start to examine the metabolic consequences of normal
pregnancy across a wide range of metabolic and
inflammatory measures. We excluded women (whether
pregnant or not) who had high fasting glucose or high
blood pressure, at levels indicative of diabetes or hyper-
tension, respectively. While we cannot be certain that
we have excluded all cases of gestational diabetes or
hypertensive disorders of pregnancy, the nature of gen-
eral population studies suggests that our results reflect
changes in normal pregnancy. The strengths of this
study include extensive molecular profiling of systemic
metabolism with replication across three independent
population-based cohorts. The highly consistent meta-
bolic findings from multiple longitudinal analyses (4, 6
and 10 years of follow-up) provide compelling additional
evidence that the metabolic aberrations are a direct re-
sult of pregnancy. We also acknowledge that the trimes-
ter analyses are cross-sectional and the pregnancy status
is assessed via questionnaires. This may slightly affect
the metabolic associations during the first trimester,
since some women may not be aware of being pregnant
in their early pregnancy and thus report themselves as
non-pregnant. Nevertheless, this information bias would
be minimal in the case of middle and late pregnancy.
Importantly, the extraordinarily large association mag-
nitudes and gradual increases in effect sizes across the
trimesters, together with the replication in individual
cohorts, strongly suggest that the effect of confounding
is minimal.
Conclusions
This work characterises the effects of pregnancy on ma-
ternal metabolism across a wide range of metabolic and
inflammatory measures. The findings are important for a
broader metabolic understanding of the physiological
changes caused by pregnancy per se and for assessing
the metabolic milieu related to normal fetal growth and
development. The metabolic effects of pregnancy are ex-
ceptionally large, gradually increase across the trimesters,
and generally normalise within 3–6 months postpartum.
These findings provide a comprehensive foundation to the
systemic molecular understanding of maternal metabol-
ism during pregnancy.
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